<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38555">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983722</url>
  </required_header>
  <id_info>
    <org_study_id>2013-5518</org_study_id>
    <nct_id>NCT01983722</nct_id>
  </id_info>
  <brief_title>Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome</brief_title>
  <official_title>Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Expanded access to Stiripentol for patients with Dravet Syndrome.  This is a treatment plan,
      and therefore patients will be monitored according to clinical standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Dravet Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stiripentol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months and older

          -  Diagnosis of Dravet Syndrome with intractable seizures

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Past history of psychoses in the form of episodes of delirium

          -  Impaired hepatic and/or renal function, defined as creatinine &gt;2 and/or
             transaminase &gt;4xULN
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>David N Franz, MD</last_name>
    <phone>513-636-4222</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David N Franz, MD</last_name>
      <phone>513-636-4222</phone>
    </contact>
    <investigator>
      <last_name>David N Franz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stiripentol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
